{"id":"W4366716971","doi":"10.1158/1538-7445.am2023-lb127","title":"Abstract LB127: VAL-083 in patients with recurrent glioblastoma treated under expanded access program","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Temozolomide; Medicine; Lomustine; Internal medicine; Oncology; Clinical trial; Adjuvant; Glioblastoma; Progression-free survival; Radiation therapy; Expanded access; Surgery; Chemotherapy; Cancer research; Vincristine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005572793,0.0002583806,0.0007675875,0.0002360267,0.0002232079,0.0004100885,0.0002661765,0.0004156758,0.001256248],"category_scores_gemma":[0.0006701141,0.0001112478,0.0004037647,0.0003488268,0.0002690894,0.0002652313,0.000282495,0.000618449,0.0002663516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000507406,"about_ca_system_score_gemma":0.0005599211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001919282,"about_ca_topic_score_gemma":0.002382561,"domain_scores_codex":[0.9997509,0.00009770554,0.00001945056,0.00003857795,0.00002955534,0.00006376189],"domain_scores_gemma":[0.9996037,0.00006989733,0.00008456674,0.0000210222,0.00002216913,0.0001986213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1639034,0.01237522,0.6538021,0.0002519404,0.000820396,0.003501162,0.0006070852,0.00127635,0.03667521,0.0001812753,0.00331533,0.1232906],"study_design_scores_gemma":[0.01411504,0.2396011,0.7325277,0.00005808148,0.0005578508,0.003270648,0.0003410919,0.001806304,0.004019731,0.0001860397,0.003473841,0.00004263775],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9993535,0.0002161916,0.00002342637,0.00004535708,0.000006149158,0.00002703259,0.00008146579,0.000006059872,0.0002409233],"genre_scores_gemma":[0.9991627,0.0001192313,0.00006197199,0.00008262992,0.00001887935,0.0000346221,0.0003487715,0.000002465425,0.0001687477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001919282,"threshold_uncertainty_score":0.004202604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1149577612169089,"score_gpt":0.4633218780303738,"score_spread":0.3483641168134649,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}